Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer
Huan Yang(Fuzhou University), Zhe Lei(Soochow University), Zhiyue Su(Soochow University), Lin Hu(Soochow University), Lingchuan Guo(Chinese Research Academy of Environmental Sciences), Jun Zhao(Beijing Institute of Technology), Wenhao Shen(Soochow University), Qi Chang(Soochow University), Yuhong Wang(Soochow University), Fei Peng(Soochow University), Kai Yang(Hubei University of Medicine)
Cited by 0
Related Papers
Carbon-Based Nanomaterials for Biomedical Applications: A Recent Study
|Frontiers in Pharmacology|2019|722
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer
|Molecular Cancer|2018|369
JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells
|International Journal of Oncology|2014|314